<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>LDL on Paul Nystrom</title><link>https://paulnystrom.com/tags/ldl/</link><description>Recent content in LDL on Paul Nystrom</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Tue, 28 Apr 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://paulnystrom.com/tags/ldl/index.xml" rel="self" type="application/rss+xml"/><item><title>Fasting Insulin</title><link>https://paulnystrom.com/posts/fasting-insulin/</link><pubDate>Tue, 28 Apr 2026 00:00:00 +0000</pubDate><guid>https://paulnystrom.com/posts/fasting-insulin/</guid><description>&lt;p>The features of metabolic syndrome have been defined since 1988 by Gerald Reaven. The 5 features include hypertension (HTN), elevated blood sugar (prediabetes or diabetes), abdominal obesity, high triglycerides (TG), and low HDL. Having any combination of 2 or more of these things significantly increases your risk of cardiovascular disease.&lt;/p>
&lt;p>Unfortunately, in my experience, these things are often ignored by primary care. There has been a decades-long push to solve for LDL and more recently ApoB. The long-standing belief is that LDL/ApoB causes heart disease. Conveniently for Big Pharma, they make a class of drug that has been worth billions that lowers LDL. These are called “statins” because the end of the generic name always ends with “-statin,” commonly known as Lipitor and Crestor among others. (Interestingly, LDL has never been a defining feature of metabolic syndrome.)&lt;/p></description></item></channel></rss>